Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil: A cross-sectional study and the implications

The Human Immunodeficiency Virus (HIV) is considered one of the greatest public health challenges given its impact on morbidity and mortality, there currently no vaccine available. costs for any have to be weighed against current preventative measures as well in reducing future infections. This was rationale behind conducting a willingness pay (WTP) study guide funding decisions. A cross-sectional conducted involving residents Northern Brazil regarding their WTP hypothetical HIV with 70% effectiveness. 634 individuals were interviewed 94% accepted use this vaccine. US$47.54 (200.00BRL). We believe these findings can contribute decision-making about pricing once becomes available discussions acceptability.